Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

Esther Kissling*, Mariette Hooiveld, Virginia Sandonis Martín, Iván Martínez-Baz, Naoma William, Ana Maria Vilcu, Clara Mazagatos, Lisa Domegan, Simon de Lusignan, Adam Meijer, Ausenda Machado, Mia Brytting, Itziar Casado, Josephine L.K. Murray, Sylvie Belhillil, Amparo Larrauri, Joan O'Donnell, Ruby Tsang, Marit de Lange, Ana Paula RodriguesMaximilian Riess, Jesús Castilla, Mark Hamilton, Alessandra Falchi, Francisco Pozo, Linda Dunford, Jade Cogdale, Tessa Jansen, Raquel Guiomar, Theresa Enkirch, Cristina Burgui, Debbie Sigerson, Thierry Blanchon, Eva María Martínez Ochoa, Jeff Connell, Joanna Ellis, Rianne van Gageldonk-Lafeber, Irina Kislaya, Angela MC Rose, Marta Valenciano, I-MOVE-COVID-19 primary care study team

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)
4 Downloads (Pure)

Abstract

We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.

Original languageEnglish
Article number2100670
Number of pages7
JournalEurosurveillance
Volume26
Issue number29
DOIs
Publication statusPublished - 22 Jul 2021

Keywords

  • COVID-19
  • Europe
  • Multicentre study
  • SARS-CoV-2
  • Test-negative design
  • Vaccine effectiveness

Fingerprint

Dive into the research topics of 'Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021'. Together they form a unique fingerprint.

Cite this